NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson’s Disease
“This first trial of ND0612 in man is a significant step in the development of a new levodopa treatment standard for Parkinson’s disease” said Oded S. Lieberman, PhD, NeuroDerm’s Chairman and CEO.